对比重组血小板生成素与白介素-11治疗白血病化疗后血小板减少症的疗效

目的：对比重组血小板生成素与白介素-11治疗白血病化疗后血小板减少症的临床疗效。方法：将我院收治的76例化疗后发生血小板减少症的白血病患者随机分为观察组与对照组各38例，对照组采用人重组白介素-11行皮下注射治疗，观察组行重组血小板生成素皮下注射治疗，比较两组患者治疗后外周血血小板变化，并分析药物应用的安全性。结果：观察组治疗后血小板恢复的最高值（215．0±27．9）＋109／L，对照组（155．9±17．4）＊10^9/L，两组比较存在显著差异（P〈0．05）；观察组患者〈50＊109／L持续时间以及70＊109／L、125＊109／L恢复时间明显短于对照组（P〈0．05）；治疗中及治疗后观察组发生不良反应4例，对照组19例，差异具有统计学意义（P〈0．05）。结论：重组血小板生成素治疗白血病患者化疗后血小板减少症可在短时间内快速提高患者外周血中血小板数量，并且应用安全性较高，不良反应发生率较低，具有临床应用及推广价值。

Objective：to compare the restructuring platelet hormone and interleukin - 11 the clinical curative effect of treatment of leukemia after chemotherapy thrombocytope- nia. Methods ：76 cases in our hospital after chemotherapy in leukemia patients with tttromhacytopenia, all the 38 eases were randomly divided into observation group and control group, control group using recombinant interleukin -linell subcutaneous injection treatment, observation group line reorganization of platelet hormone subcutaneous injection treatment, com- pared two groups after treatment in patients with peripheral blood platelet changes, and analyze the safety of drug application. Results： observation group high platelet recovery after treatment for（215.0 ＋27.9） ＊ 109/L,the control group （ 155.9 ＋ 17.4） ＊ 109/L,the two groups was significant differenee（P 〈0. 05） ;Observation group of patients duration 〈 50 ＊ 109/L and70 ＊ 109/L, 125 ＊ 109/L recovery time is much shorter than the control group （P 〈 0. 05 ） ;Treatment and after treatment in observe group of adverse reactions ,4 cases of con- trol group, statistically significant difference（ P 〈 0. 05 ）. Conclusion：the recombinant platelet for treating leukemia after chemotherapy in patients with thrembocytopenia can rapidly improve in a short time in patients with peripheral blood platelet number, and the application security is higher, lower incidence of adverse reactions, clinical application and popularization value.